Objective To investigate the role of proliferating cell nuclear antigen (PCNA) and cyclin dependent kinase 2 (CDK2) in inhibition of vascular smooth muscle cells (VSMCs) proliferation by gax gene. Methods After being transfected by AdCMV-gax, the expression of gax, PCNA and CDK2 in VSMCs were assessed. The effect of gax overexpressions on VSMCs proliferation was observed by 3 H-thymidine incorporation. Results After AdCMV-gax was transfected to VSMCs, the level of Gax protein expression was significantly higher than that before transfection. PCNA and CDK2 expressions were decreased after VSMCs were transfacted with AdCMV-gax. The level of 3 H-thymidine incorporation was decreased significantly in with AdCMV-gax transfected VSMCs compared with that in non-transfected VSMCs. Conclusion The mechanism of inhibition of VSMCs proliferation by gax gene is related with depression of expression of PCNA and CDK2.

To investigate the changs in the expressions of cellular adhesion molecules (CAMs) of the myocardium after low dose interleukin 1? (IL 1?) pretreatment and the relationship between CAMs and delayed cardioprotection, we measured the change in the expressions of intercellular adhesion molecule 1 (ICAM 1) mRNA and its proteins, the expressions of leukocyte function antigen 1(CD11a) proteins, and infiltration number of polymorphonuclear leukocytes (PMNs) in the myocardium and determined the infarct size with in situ hybridization(ISH),immunohistochemistry and enzyme methods immediately,12 hours and 24 hours after IL 1? pretreatment in a model of ischemia/reperfusion of myocardium in rats. The results showed that the expressions of ICAM 1 mRNA and its protein, CD11a protein and the PMN infiltration number were significantly higher in the ILPC and NS groups than in the control at 0～24h after IL 1? or NS pretreatment( P 0 05). The results suggested that low dose IL 1? pretreatment might inhibit the expressions in the CAMs of myocardium during the late period of ischemia /reperfusion,resulting in delayed cardioprotection.

Objective To observe the changes of serum lipids ,hs‐CRP ,MFG‐E8 and Klotho gene levels after rosuvatatin treatment in elderly patients with coronary heart disease complicating hyperlipidemia for investigating the action mechanisms of ro‐suvatatin and its application value .Methods Totally 129 elderly patients with coronary artery disease complicating hyperlipidemia in our hospital were randomly divided into two groups .The control group received only conventional treatment ,while on this basis the rosuvatatin group was given rosuvastatin 10 mg everyday ,with 2 months as a treatment cycle .Blood lipids ,hs‐CRP ,MFG‐E8 and Klotho gene levels before and after treatment were compared between the two groups .The regulation effect of rosuvatatin was investigated Results The blood lipod ,hs‐CRP ,MFG‐E8 and Klotho before treatment had no obvious difference between the two groups .The levels of TC ,LDL‐C and TG after treatment in the rosuvatatin group were significantly decreased compared with the control group ,while the HDL‐C level was significantly increased ,the differences were statistically significant (P<0 .05) .In addi‐tion ,the hs‐CRP level after treatment in the rosuvatatin group was significantly lower than that in the control group (P<0 .05) . Compared with the control group ,the levels of MFG‐E8 and Klotho after treatment in the rosuvatatin group were increased ,the difference was statistically significant (P<0 .05) .Conclusion Rosuvastatin could decrease the blood lipid and hs‐CRP levels ,up‐regulates the MFG‐E8 and Klotho levels ,alleviates the inflammatory reaction and has the anti‐vascular aging effect ,thus effectively treats the patients with coronary heart disease complicating hyperlipidemia .

Objective To evaluate the therapeutic efficacy and safety of transcatheter closure of atrial septal defect (ASD) and patent ductus arteriosus (PDA) using Amplatzer occluder. Methods Routine cardiac catheterization and angiography were performed in 50 patients (23 male, 27 female, age ranging from 3 to 64 years old), including 19 cases of ASD and 31 cases of PDA under local or general anesthesia. After balloon sizing of the ASD, the optimal Amplazter septal occluder (ASO) was transmitted into the left atrial, and the left and right disks were released in turn. The Amplatzer occluder was completely released after transthoracic echocardiography confirmed that there was no residual shunts or new onset mitral valve regurgitation. The Amplatzer duct occluder (ADO) size was selected according to the narrowest point of PDA measured by angiography, and the occluder was released after the repeated angiography showed no residual shunts. Results ① The mean diameter of the ASD measured by balloon was 13-31 (23?6) mm and the diameter of ASO was (17-40) mm. The immediate closure rate was 100%. ② Angiography confirmed that closure of the ductus using ADO was achieved in 30 patients, and closure of the large size (12 mm) was achieved in 1 case of PDA patient using ASO (17 mm). No complications were encountered. Conclusion Transcatheter closure of ASD and PDA using Amplatzer device, with the advantages of simple operation, confirmative occlusion efficacy, minimal invasiveness, wide indications, and less complications, has a bright future of clinical application.